The initiation of coverage by a reputable analyst with an Outperform rating and a significant price target suggests a positive outlook for Kymera Therapeutics. This is likely to generate investor interest and could lead to a short-term increase in the stock price, reflecting the analyst's confidence in the company's future performance.